| 1 |
Yu WM, Li R, Sun BL, Du JK, Tuo HF. Primary hepatic neuroendocrine tumour with multiple liver metastases: A case report with literature review. Int J Surg Case Rep 2021;89:106590. [PMID: 34784532 DOI: 10.1016/j.ijscr.2021.106590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 2 |
董 玉. Clinical Characteristics and Treatment of Hepatic Neurorndorine Neoplasms. ACM 2021;11:5391-5397. [DOI: 10.12677/acm.2021.1111797] [Reference Citation Analysis]
|
| 3 |
BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, Vankina R, Hsu CD, Jang B, Pan K, Lund JL, Starbuck E, Shahrokni A. The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. J Geriatr Oncol 2020;11:369-79. [PMID: 31932259 DOI: 10.1016/j.jgo.2019.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 4 |
Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One 2019;14:e0218953. [PMID: 31237925 DOI: 10.1371/journal.pone.0218953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 5 |
Ge W, Zhou D, Zhu L, Song W, Wang W. Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors. J Cancer 2018;9:4783-90. [PMID: 30588264 DOI: 10.7150/jca.25908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 6 |
Hasskarl J. Everolimus. Recent Results Cancer Res 2018;211:101-23. [PMID: 30069763 DOI: 10.1007/978-3-319-91442-8_8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 7 |
Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 8 |
Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Oncologist 2019;24:38-46. [PMID: 29794066 DOI: 10.1634/theoncologist.2017-0622] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 9 |
Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology 2018;18:198-203. [PMID: 29361429 DOI: 10.1016/j.pan.2018.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 10 |
Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer 2018;124:1992-2000. [PMID: 29451701 DOI: 10.1002/cncr.31192] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Watson ML, Schroader BK, Nelkin HD. Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs. Side Effects of Drugs Annual 2018. [DOI: 10.1016/bs.seda.2018.07.006] [Reference Citation Analysis]
|
